Table 1

Best overall response by indication (investigator assessed according to RECIST V.1.1)

CharacteristicMelanomaNSCLC
Clinical benefit of prior anti-PD-1/PD-L1 therapyAll (N=16)Clinical benefit of prior anti-PD-1/PD-L1 therapyAll (N=17)
Best overall response, n (%)DCB (N=6)NDCB (N=10)Unknown (N=0)DCB (N=7)NDCB (N=9)Unknown (N=1)
Stable disease (SD)2 (33.3)1 (10.0)3 (18.8)3 (42.9)2 (22.2)1 (100.0)6 (35.3)
Progressive disease (PD)4 (66.7)8 (80.0)12 (75.0)3 (42.9)2 (22.2)05 (29.4)
Unknown01 (10)1 (6.3)1 (14.3)5 (55.6)06 (35.3)
Overall response rate, %*0000000
Disease control rate, % (90% CI)†33.3
(6.3 to 72.9)
10.0
(0.5 to 39.4)
18.8
(5.3 to 41.7)
42.9
(12.9 to 77.5)
22.2
(4.1 to 55.0)
100.0
(5.0 to 100.0)
35.3
(16.6 to 58.0)
  • *CR or PR.

  • †CR or PR or SD or NCRNPD.

  • CR, complete response; DCB, durable clinical benefit; NCRNPD, neither CR nor PD; NDCB, non-DCB; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumours.